EA201691498A1 - Новая мишень для лечения и профилактики диабета - Google Patents

Новая мишень для лечения и профилактики диабета

Info

Publication number
EA201691498A1
EA201691498A1 EA201691498A EA201691498A EA201691498A1 EA 201691498 A1 EA201691498 A1 EA 201691498A1 EA 201691498 A EA201691498 A EA 201691498A EA 201691498 A EA201691498 A EA 201691498A EA 201691498 A1 EA201691498 A1 EA 201691498A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alms1
treatment
αpkc
relates
present
Prior art date
Application number
EA201691498A
Other languages
English (en)
Inventor
Венсан Марион
Николай Петровски
Original Assignee
Юниверсите Де Стразбур
Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль
Ваксин Пти Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсите Де Стразбур, Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль, Ваксин Пти Лтд. filed Critical Юниверсите Де Стразбур
Publication of EA201691498A1 publication Critical patent/EA201691498A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)

Abstract

Настоящее изобретение относится к идентификации ALMS1 как недостающего игрока, участвующего в регуляции инсулин-опосредованного поглощения глюкозы через GLUT4-сортировочные везикулы, и к отрицательной регуляции ALMS1 с помощью αPKC. Соответственно, настоящее изобретение относится к молекуле, способной предотвращать связывание αPKC с ALMS1 для применения при лечении или профилактике сахарного диабета, в частности сахарного диабета 2 типа. Кроме того, настоящее изобретение относится к способу идентификации молекулы, способной предотвращать связывание αPKC c ALMS1.
EA201691498A 2014-01-29 2015-01-29 Новая мишень для лечения и профилактики диабета EA201691498A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14153017 2014-01-29
PCT/EP2015/051856 WO2015114062A1 (en) 2014-01-29 2015-01-29 New target for diabetes treatment and prevention

Publications (1)

Publication Number Publication Date
EA201691498A1 true EA201691498A1 (ru) 2017-02-28

Family

ID=50000917

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691498A EA201691498A1 (ru) 2014-01-29 2015-01-29 Новая мишень для лечения и профилактики диабета

Country Status (8)

Country Link
US (2) US10821159B2 (ru)
EP (2) EP3501531A1 (ru)
CN (1) CN106456700B (ru)
BR (1) BR112016017444A2 (ru)
CA (1) CA2937447A1 (ru)
EA (1) EA201691498A1 (ru)
ES (1) ES2714355T3 (ru)
WO (1) WO2015114062A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3501531A1 (en) 2014-01-29 2019-06-26 Université de Strasbourg New target for diabetes treatment and prevention
EP3421485A1 (en) * 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
JP7362611B2 (ja) 2017-12-14 2023-10-17 ユニヴェルシテ・ドゥ・ストラスブール 非アルコール性脂肪肝疾患及び線維症の治療及び予防のためのペプチド
WO2020127904A1 (en) 2018-12-21 2020-06-25 Universite De Strasbourg Peptides for treatment and prevention of diabetes and associated disorders
CN112904014B (zh) * 2019-12-04 2023-01-13 张曼 尿液TBC1D5a蛋白及其多肽片段在正常妊娠或妊娠糖尿病中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0934331B1 (de) 1996-08-30 2002-11-27 Jens Peter Fürste Spiegelselektion und spiegelevolution von nucleinsäuren
US6225120B1 (en) * 1997-05-15 2001-05-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
US6833436B2 (en) * 1997-05-21 2004-12-21 Children's Medical Center Corporation Short peptides which selectively modulate the activity of serine/threonine kinases
AU6059099A (en) * 1998-09-25 2000-04-17 Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
WO2001044497A2 (en) * 1999-12-02 2001-06-21 University Of Dundee Protein kinase regulation
US7029892B1 (en) * 2000-07-19 2006-04-18 Amgen, Inc. Serine threonine kinase member, h2520-59
US20020162127A1 (en) * 2001-01-30 2002-10-31 Yizhong Gu Human protein kinase domain-containing protein
US20050214757A1 (en) * 2001-10-15 2005-09-29 Wilson David I Diagnosis and therapy of conditions by detection or modulation of the alms1 gene or protein
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
ATE392433T1 (de) * 2003-07-17 2008-05-15 Univ Dundee Verfahren zur anwendung eines an lkb1/strad/mo25- komplexes
US7902330B2 (en) * 2004-02-13 2011-03-08 Albert Einstein College Of Medicine Of Yeshiva University Protein kinase inhibitors and methods for identifying same
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
US8575307B2 (en) * 2005-06-29 2013-11-05 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
JP2009540013A (ja) * 2006-06-15 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アニリノ−４−（複素環）アミノ−ピリミジン
WO2008005487A2 (en) * 2006-06-30 2008-01-10 The Board Of Trustees Of The Leland Peptide sequences for modulation of protein kinase c
RU2502520C2 (ru) * 2007-07-30 2013-12-27 Хилор Лтд. Фармацевтическая композиция и относящиеся способы
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGATURE OF STAPLED POLYPEPTIDES
WO2010033617A2 (en) 2008-09-16 2010-03-25 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
WO2011057063A2 (en) * 2009-11-06 2011-05-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for quantitatively monitoring lipids
GB201103631D0 (en) 2011-03-03 2011-04-13 Univ Leeds Identification of candidate therapeutics
US8580769B2 (en) * 2011-03-10 2013-11-12 The United States Of America As Represented By The Department Of Veterans Affairs Treatment of obesity, metabolic syndrome, and diabetes with protein kinase C inhibitors
US9260484B2 (en) 2011-06-15 2016-02-16 Ohio State Innovation Foundation Small molecule composite surfaces as inhibitors of protein-protein interactions
WO2013152198A1 (en) * 2012-04-04 2013-10-10 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
EP3501531A1 (en) 2014-01-29 2019-06-26 Université de Strasbourg New target for diabetes treatment and prevention
EP3421485A1 (en) 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
EP3437651A1 (en) 2017-08-03 2019-02-06 Université de Strasbourg Peptides for treatment and prevention of nonalcoholic fatty liver disease
JP7362611B2 (ja) 2017-12-14 2023-10-17 ユニヴェルシテ・ドゥ・ストラスブール 非アルコール性脂肪肝疾患及び線維症の治療及び予防のためのペプチド

Also Published As

Publication number Publication date
CN106456700B (zh) 2020-02-18
CN106456700A (zh) 2017-02-22
EP3099312A1 (en) 2016-12-07
EP3501531A1 (en) 2019-06-26
US11826403B2 (en) 2023-11-28
WO2015114062A1 (en) 2015-08-06
US20170000857A1 (en) 2017-01-05
EP3099312B1 (en) 2018-12-05
US10821159B2 (en) 2020-11-03
US20210069301A1 (en) 2021-03-11
BR112016017444A2 (pt) 2017-10-10
ES2714355T3 (es) 2019-05-28
CA2937447A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
EA201890269A1 (ru) Гербицидная композиция, содержащая цинметилин и напропамид
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2021007663A (es) Molecula de union al antigeno especifico para el tejido objetivo.
EA202092187A1 (ru) Способы лечения эпителиоидно-клеточных опухолей
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
EA201990360A1 (ru) Аналоги амилина
EA201691498A1 (ru) Новая мишень для лечения и профилактики диабета
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
EA201791467A1 (ru) Водный офтальмологический раствор
EA201791348A1 (ru) Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
EA201791174A1 (ru) Антимикотическое соединение
EA201891342A1 (ru) Изоиндольные соединения
WO2016089886A3 (en) Methods for treating dry eye disease by administering an il-6r antagonist
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
CY1122457T1 (el) Μη πτητικες οφθαλμικες συνθεσεις, ειδικες για τη θεραπεια της ξηροφθαλμιας
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
BR112016023519A2 (pt) inibidor de sinalização de wnt/ß-catenina, composição farmacêutica e método de tratamento e/ou prevenção de uma patologia definida por malformação vascular
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201692045A1 (ru) Производное фенантролинфосфоновой кислоты и способ его получения и применения
MX2016008968A (es) Compuestos organicos.
EA201700097A1 (ru) Пептид для лечения сахарного диабета 2-го типа и его осложнений
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
ES2721003T3 (es) Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis